MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) Total liabilities 2016–2024
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) total liabilities at each fiscal year-end, per SEC filings.
$5.9MFY2024 · since FY2016: $2.3M → $5.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | $5.9M | -28.4% |
| FY2023 | $8.2M | -7.4% |
| FY2022 | $8.8M | +22.0% |
| FY2021 | $7.2M | +0.7% |
| FY2020 | $7.2M | +89.1% |
| FY2019 | $3.8M | +1.6% |
| FY2018 | $3.7M | +40.3% |
| FY2017 | $2.7M | +14.3% |
| FY2016 | $2.3M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More MTNB financial trends
MTNB RevenueMTNB Net incomeMTNB Net marginMTNB Gross profitMTNB Gross marginMTNB Operating incomeMTNB Operating marginMTNB Operating cash flowMTNB Free cash flowMTNB Capital expendituresMTNB Return on equityMTNB Stock buybacksMTNB Dividends paidMTNB Total assetsMTNB Shareholders’ equityMTNB overview →